Asymmetric dimethylarginine in hematological malignancies: A preliminary study

Leukemia and Lymphoma

Volumn 49, Issue 12, 2008, Pages 2316-2320

  Szuba, Andrzej ^a   Chachaj, Angelika ^a   Wróbel, Tomasz ^a   Dzietczenia, Justyna ^a   Mazur, Grzegorz ^a   Antonowicz Juchniewicz, Jolanta ^a   Kuliczkowski, Kazimierz ^a   Andrzejak, Ryszard ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Dimethylarginine dimethylaminohydrolase; L arginine; Nitric oxide; Nitric oxide synthase; Protein arginine methyltransferase; Symmetric dimethylarginine

Indexed keywords

ARGININE DERIVATIVE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AMINO ACID ANALYSIS; AMINO ACID SYNTHESIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; VOLUNTEER;

ADULT; AGED; ARGININE; CASE-CONTROL STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 57449105050     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802510323     Document Type: Article

References (42)

1. McBride, A. E. and Silver, P. A. (2001) State of the arg: Protein methylation at arginine comes of age. Cell, 106, pp. 5-8.
2. Vallance, P., Leone, A., Calver, A., Collier, J. and Moncada, S. (1992) Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol, 20, pp. S60-S62.
3. Mehta, S., Stewart, D. J., Langleben, D. and Levy, R. D. (1995) Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation, 92, pp. 1539-1545.
4. Closs, E. I., Basha, F. Z., Habermeier, A. and Forstermann, U. (1997) Interference of -arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide, 1, pp. 65-73.
5. Ignarro, L. J., Cirino, G., Casini, A. and Napoli, C. (1999) Nitric oxide as a signaling molecule in the vascular system: An overview. J Cardiovasc Pharmacol, 34, pp. 879-886.
6. Cooke, J. P. and Losordo, D. W. (2002) Nitric oxide and angiogenesis. Circulation, 105, pp. 2133-2135.
7. Boger, R. H. (2006) Live and let die: Asymmetric dimethylarginine and septic shock. Crit Care, 10, p. 169.
8. Cauwels, A. (2007) Nitric oxide in shock. Kidney Int, 72, pp. 557-565.
9. Lind, D. S. (2004) Arginine and cancer. J Nutr, 134, pp. 2837S-2841S.
10. Billard, C., Quiney, C., Tang, R., Kern, C., Ajchenbaum-Cymbalista, F. Dauzonne, D. et al. (2003) The inducible NO synthase is downregulated during apoptosis of malignant cells from B-cell chronic lymphocytic leukemia induced by flavopiridol and polyphenols. Ann N Y Acad Sci, 1010, pp. 381-383.
11. Boger, R. H. and Zoccali, C. (2003) ADMA: A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl, 4, pp. 23-28.
12. Kimoto, M., Whitley, G. S., Tsuji, H. and Ogawa, T. (1995) Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem (Tokyo), 117, pp. 237-238.
13. Wang, J., Sim, A. S., Wang, X. L. and Wilcken, D. E. (2006) L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell Mol Life Sci, 63, pp. 2838-2846.
14. Miyazaki, H., Matsuoka, H., Cooke, J. P., Usui, M., Ueda, S. Okuda, S. et al. (1999) Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation, 99, pp. 1141-1146.
15. Anthony, S., Leiper, J. and Vallance, P. (2005) Endogenous production of nitric oxide synthase inhibitors. Vasc Med, 10, pp. S3-S9.
16. Valkonen, V. P., Paiva, H., Salonen, J. T., Lakka, T. A., Lehtimaki, T. Laakso, J. et al. (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet, 358, pp. 2127-2128.
17. Boger, R. H. (2005) Asymmetric dimethylarginine (ADMA) and cardiovascular disease: Insights from prospective clinical trials. Vasc Med, 10, pp. S19-S25.
18. Zoccali, C., Bode-Boger, S., Mallamaci, F., Benedetto, F., Tripepi, G. Malatino, L. et al. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet, 358, pp. 2113-2117.
19. Schnabel, R., Blankenberg, S., Lubos, E., Lackner, K. J., Rupprecht, H. J. Espinola-Klein, C. et al. (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. Circ Res, 97, pp. e53-e59.
20. Mittermayer, F., Krzyzanowska, K., Exner, M., Mlekusch, W., Amighi, J. Sabeti, S. et al. (2006) Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol, 26, pp. 2536-2540.
21. Krzyzanowska, K., Mittermayer, F., Wolzt, M. and Schernthaner, G. (2007) Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care, 30, pp. 1834-1839.
22. Nijveldt, R. J., Siroen, M. P., Teerlink, T. and van Leeuwen, P. A. (2004) Elimination of asymmetric dimethylarginine by the kidney and the liver: A link to the development of multiple organ failure?. J Nutr, 134, pp. 2848S-2852S.
23. Boger, R. H. (2003) Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med, 41, pp. 1467-1472.
24. Boger, R. H., Bode-Boger, S. M., Szuba, A., Tsao, P. S., Chan, J. R. Tangphao, O. et al. (1998) Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation, 98, pp. 1842-1847.
25. Cockcroft, D. W. and Gault, M. H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, pp. 31-41.
26. Boisvert, F. M., Cote, J., Boulanger, M. C. and Richard, S. (2003) A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics, 2, pp. 1319-1330.
27. Wu, G. and Morris Jr, S. M. (1998) Arginine metabolism: Nitric oxide and beyond. Biochem J, 336, pp. 1-17.
28. Wu, G., Meininger, C. J., Knabe, D. A., Bazer, F. W. and Rhoads, J. M. (2000) Arginine nutrition in development, health and disease. Curr Opin Clin Nutr Metab Care, 3, pp. 59-66.
29. Murray-Rust, J., Leiper, J., McAlister, M., Phelan, J., Tilley, S. Santa Maria, J et al. (2001) Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol, 8, pp. 679-683.
30. Ito, A., Tsao, P. S., Adimoolam, S., Kimoto, M., Ogawa, T. and Cooke, J. P. (1999) Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation, 99, pp. 3092-3095.
31. Giles, G. I. (2006) The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des, 12, pp. 4427-4443.
32. Sydow, K. and Munzel, T. (2003) ADMA and oxidative stress. Atheroscler Suppl, 4, pp. 41-51.
33. Konukoglu, D., Firtina, S. and Serin, O. (2008) The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. Metabolism, 57, pp. 110-115.
34. Zoccali, C., Benedetto, F. A., Maas, R., Mallamaci, F., Tripepi, G. Malatino, L. S. et al. (2002) Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol, 13, pp. 490-496.
35. Oeffinger, K. C. (2008) Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?. Pediatr Blood Cancer, 50, pp. 462-467.
36. Dengel, D. R., Ness, K. K., Glasser, S. P., Williamson, E. B., Baker, K. S. and Gurney, J. G. (2008) Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol, 30, pp. 20-25.
37. Abbasi, F., Asagmi, T., Cooke, J. P., Lamendola, C., McLaughlin, T. Reaven, G. M. et al. (2001) Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol, 88, pp. 1201-1203.
38. Stuhlinger, M. C. and Stanger, O. (2005) Asymmetric dimethyl-L-arginine (ADMA): A possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab, 6, pp. 3-14.
39. Perticone, F., Sciacqua, A., Maio, R., Perticone, M., Maas, R. Boger, R. H. et al. (2005) Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol, 46, pp. 518-523.
40. Nijveldt, R. J., Teerlink, T. and van Leeuwen, P. A. (2003) The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr, 22, pp. 99-104.
41. Cooke, J. P. (2006) Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of angiogenesis. Eur J Clin Pharmacol, 62, pp. 115-121.
42. Grabon, W. (2006) [Arginine as a crucial amino acid in carcinogenesis and tumor growth]. Postepy Hig Med Dosw (Online), 60, pp. 483-489.